It is currently Fri Aug 29, 2014 11:30 pm

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

View on Tysabri

The NMSS website includes the following request to provide views on Tysabri to the FDA.

The request is odd as it assumes we know what the risks / benefits are. The current CRAB treatments are modest at best so we are all after better treatments but who knows how much better Tysabri is (apart from the trials data and some feedback from some users)!


http://www.nationalmssociety.org/news_tysabri.asp


Ian
Read more : View on Tysabri | Views : 9759 | Replies : 51


Don't cry HarryZ

Biogen are confident that Tysabri could be back by June 2006.

Get ready to sell you Biogen shares HarryZ :lol:


http://c.moreover.com/click/here.pl?j409634062&w=464753
Read more : Don't cry HarryZ | Views : 2011 | Replies : 4




Death and Dividends: The Tysabri Debacle

Death and Dividends: The Tysabri Debacle

By Ashton Embry


For the last three to four years neurologists have been talking about the coming of a much more effective drug for MS. That drug was first called Antegren and then Tysabri. The story of Tysabri illustrates some risky and unsavory aspects of the search for an effective drug for MS.

Tysabri is a humanized, monoclonal antibody that is produced by transgenic goats in their milk. A ...
Read more : Death and Dividends: The Tysabri Debacle | Views : 1701 | Replies : 2


Monoclonal Antibodies (mAbs)

Came across this article on monoclonal antibodies. Interesting to say the least.

Harry

_________________________

Nature Biotechnology 23, 1025 (2005)
doi:10.1038/nbt0905-1025
King in the kingdom of uncertainty



Monoclonal antibodies (mAbs) are not good drugs, at least they are not good drugs in any conventional sense. Many of the fundamental qualities of mAbs are just the sort of characteristics that used to make pharmaceutical manufacturers run a mile.

Most fundamentally, they are biological molecules and hence intrinsically ...
Read more : Monoclonal Antibodies (mAbs) | Views : 1501 | Replies : 0


On way back ? But fewer sales ??

Two articles of interest from The Boston Globe about Tysabri commercials.

Biogen Idec to seek stronger warning label for MS drug, CEO says
By Mark Jewell, AP Business Writer August 31, 2005

CAMBRIDGE, Mass. --The head of Biogen Idec Inc. said in an interview Wednesday his company will recommend to regulators within a month that the warning label be strengthened on a multiple sclerosis drug the company hopes to return to the market despite safety ...
Read more : On way back ? But fewer sales ?? | Views : 2036 | Replies : 2


Back late 05 or early 06?

A link to another Tysabri article. This one (like some others) considers that the treatment could be re-introduced in the US in late 05 or early 06.

http://c.moreover.com/click/here.pl?j372244535&w=464753


Try some HarryZ - you know you want to! :lol:

Bromley
Read more : Back late 05 or early 06? | Views : 2073 | Replies : 4


Tysabri Still Down, But Not Out

Market Scan
Tysabri Still Down, But Not Out
Matthew Herper, 08.09.05, 10:50 AM ET

Biogen Idec

After months of waiting, Biogen Idec (nasdaq: BIIB - news - people ) and Elan (nyse: ELN - news - people ) are finally having a good day--but investors should be careful not to be too exuberant about hopes for their beleaguered drug.

The two biotech firms have finished their safety review of Tysabri, the multiple sclerosis drug that ...
Read more : Tysabri Still Down, But Not Out | Views : 1695 | Replies : 0


Biogen, Elan sued for allegedly concealing MS drug risks

Biogen, Elan sued for allegedly concealing MS drug risks

http://www.bizjournals.com/boston/stori ... 1752087487

Biogen, Elan sued for allegedly concealing MS drug risks

Boston Business Journal

A patient is suing Biogen Idec and Elan Corp. PLC, accusing them of concealing risks of their multiple-sclerosis drug Tysabri before withdrawing it from the market.

Bloomberg News reported that the patient filed a federal court suit in San Francisco claiming both companies knew the ...
Read more : Biogen, Elan sued for allegedly concealing MS drug risks | Views : 1537 | Replies : 0


NEJM articles and editorial

Hi Everyone -

Thought I would point out that the New England Journal of Medicine out today has three articles following up on Tysabri and PML along with an editorial. I only get the abstracts and can't really tell what the key points are, but maybe one of you has better access or better insight into what is written.

- Arcee
Read more : NEJM articles and editorial | Views : 1817 | Replies : 3


 

Login  •  Register


Statistics

Total posts 219610 • Total topics 22672 • Total members 14284


Contact us | Terms of Service